



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Louis Diehl, M.D.**

Committee: **Oncologic Drugs Advisory Committee**

Meeting Date: **April 22, 2022**

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On April 22nd, the committee will discuss supplemental new drug application (sNDA) 213176/S-002, for Ukoniq (umbralisib) tablets, and biologics license application (BLA) 761207, for ublituximab injection, both submitted by TG Therapeutics, Inc. The proposed indication (use) for these two products is in combination for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition, the committee will also discuss the existing umbralisib indications in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma under 21 CFR 314.500 (subpart H, accelerated approval regulations).

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
contract/grant	TG Therapeutics, party to the matter	Dr. Diehl is not aware of the funding amount being provided to Duke University
contract/grant	TG Therapeutics, party to the matter	Dr. Diehl is not aware of the funding amount being provided to Duke University
contract/grant	BeiGene, competing firm	Dr. Diehl is not aware of the funding amount being provided to Duke University
contract/grant	Celgene, competing firm	Dr. Diehl is not aware of the funding amount being provided to Duke University

